Gentian Diagnostics AS
The answer first
Does Gentian Diagnostics beat the market?
No, Gentian Diagnostics has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 38% of Nordic stocks
- Quality62
- Value21
- Trend54
No. 84 of 195 in healthcare
Expectations in the price
High expectations
For the share to return about 9% a year from today's price, the cash Gentian Diagnostics keeps must grow about 13% a year for 10 years.
Max for seven days
Follow Gentian Diagnostics with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 18 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Gentian Diagnostics
Your first answer is free, no account needed.
Do you own Gentian Diagnostics, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Gentian Diagnostics and a few more. Free, no card.
Super Stock+44.6%In short
- Gentian Diagnostics has fallen 27.5% over the past year, including dividends.
- Overall, Gentian Diagnostics ranks better than 38% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 58.4%. The price is 53.4% below its peak now.
Who owns Gentian Diagnostics? See the major shareholders and their stakes
What do analysts think of Gentian Diagnostics?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 38% of Nordic stocks.
No. 84 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 102 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.19
- Asset turnoverSales divided by everything the company owns0.82
- Return on equityProfit divided by equity−2.7%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 96 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity3.1
- P/SPrice divided by sales3.1
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flow23.8
The ranking is built on P/E, P/B and P/S.
Medium The share price has moved about like most stocks over the last year.
No. 71 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+1.0%
- 6 months+9.5%
- 9 months−0.7%
- 12 months−27.5%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Gentian Diagnostics
One fund we follow owns Gentian Diagnostics. The share is how much of the fund the stock makes up.
- Sweden1
From the funds' latest known holdings.
About Gentian Diagnostics
Gentian Diagnostics AS is a company in healthcare, listed on Oslo Børs. The share trades in NOK. It has around 63 employees.
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. It offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Calprotectin Immunoassay, a turbidimetric assay used for the measurement of circulating calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay…


See the full analysis of Gentian Diagnostics.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card